Navigation Links
Access Pharmaceuticals Retains Edelman as Public Relations Firm
Date:8/5/2011

DALLAS and NEW YORK, Aug. 5, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has hired Edelman, the leading full service global public relations firm, to support its media outreach initiatives.  Edelman will assist Access in implementing a media communications outreach program primarily aimed at introducing MuGard and building awareness of its ability to treat oral mucositis, a potentially debilitating disease which can cause painful inflammation and lesions of the mucous membranes lining the mouth and GI tract.

"Edelman has a great track record in conveying the value of company pipelines to a broad range of media outlets," said Jeffrey Davis, Chief Executive Officer, Access Pharmaceuticals, Inc.  He continued, "We believe we are at the right time in the Access story and the commercialization of MuGard to expand our reach in within trade and consumer publications.   As we continue to execute on our strategy of growing the MuGard brand, capitalizing on Edelman's strategic skills, creativity and global reach to communicate the benefit and control it provides cancer patients will be key in achieving our MuGard education and communications objectives."

Bruce Hayes, general manager of Health for Edelman in the company's New York office stated, "We are pleased that Access has made the decision to join our portfolio of health clients.  An emerging player in the cancer supportive care industry, Access is helping patients who suffer from oral mucositis. We are confident that our public engagement strategies will assist in building the MuGard brand and raising Access' visibility among its key audiences."

About EdelmanEdelman is the world's largest independent public relations firm, with wholly-owned offices in 53 cities and 3,700 employees worldwide. Edelman was named Advertising Age's top-ranked PR firm of the decade and one of its "2010 A-List Agencies" and "2010 Best Places to Work;" PRWeek's "2011 Large PR Agency of the Year" and "2009 Agency of the Year;" European Excellence Awards' "2010 Agency of the Year;" Holmes Report's "Agency of the Decade" and "2009 Asia Pacific Consultancy of the Year;" and among Glassdoor's top five "2011 Best Places to Work." Visit http://www.edelman.com for more information.

About Access Pharmaceuticals, Inc.Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. WeinbergerDirector of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unrestricted Access to Advanced Imaging a Top Priority for Consumers
2. Elsevier Launches Next Generation Codifa, Providing Italian Doctors with Real Time Access to Critical Drug Information
3. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
4. Diverse Elders Coalition Urges President Obama, Congressional Leaders to Protect Seniors Access to Home Healthcare
5. Concentric Medical Launches DAC® 070, A New Distal Access Catheter
6. Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
7. Access Pharmaceuticals MuGard Included in TRICARE Prescription Drug Coverage
8. Pharmacy Choice & Access Now Coalition Urges Full Implementation of Senate Bill 7
9. Access Pharmaceuticals MuGard Added to CVS Caremarks Pharmacy Benefit Network
10. Kimberly-Clark Launches KimVent Multi-Access Port Closed Suction System
11. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... RnRMarketResearch.com adds "Asthma - Pipeline ... of Asthma therapy at various stages, therapeutics assessment by ... (RoA) and molecule type, along with latest updates, and ... players involved in the therapeutic development for Asthma and ... Complete report on H1 2016 pipeline review of Asthma ...
(Date:5/30/2016)... 2016 According to ... Market by Technology (Single-factor (Fingerprint, Face, Iris, ... (Workforce Management), End User (Hospitals, Healthcare Institutions) ... MarketsandMarkets, the market is projected to reach ... 1,182.6 Million by 2016, at a CAGR ...
(Date:5/30/2016)... May 30, 2016 The ... USD 7.3 billion by 2024, according to a ... increasing natality rate, the growing malnutrition coupled with ... and gastro-intestinal tract diseases are expected to boost ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... ... May 31, 2016 , ... In ... can describe personality traits in humans. Using presidential candidate Donald Trump as an ... vitality. , “AstroNumerology is not about adding numbers up,” says Kalsi. “It ...
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows ... Center – Somers Point, NJ. The new clients range in bed size from 57 ... Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical center ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... Washington, NY (PRWEB) , ... May 31, 2016 , ... ... other essential nutrients to on the go individuals and dedicated athletes, continues to transform ... , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline ...
Breaking Medicine News(10 mins):